Alimera Sciences, Inc. (ALIM)
Company Description
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals.
It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors.
It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases.
Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Country | United States |
Founded | 2003 |
IPO Date | Apr 22, 2010 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 154 |
CEO | Richard S. Eiswirth Jr. |
Contact Details
Address: 6310 Town Square, Suite 400 Alpharetta, Georgia 30005 United States | |
Phone | 678-990-5740 |
Website | alimerasciences.com |
Stock Details
Ticker Symbol | ALIM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001267602 |
CUSIP Number | 016259202 |
ISIN Number | US0162592028 |
Employer ID | 20-0028718 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Richard S. Eiswirth Jr. | Chief Executive Officer and Director |
David R. Holland | Co-Founder, Chief Marketing Officer and Senior Vice President of Corporate Communications and Managed Markets |
Dr. Philip Ashman Ph.D. | President of International Operations |
Todd Michael Wood | President of U.S. Operations |
Elliot Maltz CPA | Chief Financial Officer and Treasurer |
Jason Werner | Chief Operating Officer |
Christopher S. Visick | Vice President, General Counsel and Secretary |
Dr. David Dyer M.D. | Chief Retina Specialist |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 8, 2024 | 10-K | Annual Report |
Mar 7, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |